Chao Guo1, Ya-Yue Gao1, Qian-Qian Ju1, Chun-Xia Zhang1, Ming Gong1, Zhen-Ling Li2. 1. Department of Hematology, China-Japan Friendship Hospital, Yinghua East Street, Beijing, 100029, China. 2. Department of Hematology, China-Japan Friendship Hospital, Yinghua East Street, Beijing, 100029, China. lizhenling03@163.com.
Abstract
BACKGROUND: IGHV mutation status is a crucial prognostic biomarker for CLL. In the present study, we investigated the transcriptomic signatures associating with IGHV mutation status and CLL prognosis. METHODS: The co-expression modules and hub genes correlating with IGHV status, were identified using the GSE28654, by 'WGCNA' package and R software (version 4.0.2). The over-representation analysis was performed to reveal enriched cell pathways for genes of correlating modules. Then 9 external cohorts were used to validate the correlation of hub genes expression with IGHV status or clinical features (treatment response, transformation to Richter syndrome, etc.). Moreover, to elucidate the significance of hub genes on disease course and prognosis of CLL patients, the Kaplan-Meier analysis for the OS and TTFT of were performed between subgroups dichotomized by the median expression value of individual hub genes. RESULTS: 2 co-expression modules and 9 hub genes ((FCRL1/FCRL2/HELQ/EGR3LPL/LDOC1/ZNF667/SOWAHC/SEPTIN10) correlating with IGHV status were identified by WGCNA, and validated by external datasets. The modules were found to be enriched in NF-kappaB, HIF-1 and other important pathways, involving cell proliferation and apoptosis. The expression of hub genes was revealed to be significantly different, not only between CLL and normal B cell, but also between various types of lymphoid neoplasms. HELQ expression was found to be related with response of immunochemotherapy treatment significantly (p = 0.0413), while HELQ and ZNF667 were expressed differently between stable CLL and Richter syndrome patients (p < 0.0001 and p = 0.0278, respectively). By survival analysis of subgroups, EGR3 expression was indicated to be significantly associated with TTFT by 2 independent cohorts (GSE39671, p = 0.0311; GSE22762, p = 0.0135). While the expression of HELQ and EGR3 was found to be associated with OS (p = 0.0291 and 0.0114 respectively).The Kras, Hedgehog and IL6-JAK-STAT3 pathways were found to be associating with the expression of hub genes, resulting from GSEA. CONCLUSIONS: The expression of HELQ and EGR3 were correlated with IGHV mutation status in CLL patients. Additionally, the expression of HELQ/EGR3 were prognostic markers for CLL associating with targetable cell signaling pathways.
BACKGROUND: IGHV mutation status is a crucial prognostic biomarker for CLL. In the present study, we investigated the transcriptomic signatures associating with IGHV mutation status and CLL prognosis. METHODS: The co-expression modules and hub genes correlating with IGHV status, were identified using the GSE28654, by 'WGCNA' package and R software (version 4.0.2). The over-representation analysis was performed to reveal enriched cell pathways for genes of correlating modules. Then 9 external cohorts were used to validate the correlation of hub genes expression with IGHV status or clinical features (treatment response, transformation to Richter syndrome, etc.). Moreover, to elucidate the significance of hub genes on disease course and prognosis of CLL patients, the Kaplan-Meier analysis for the OS and TTFT of were performed between subgroups dichotomized by the median expression value of individual hub genes. RESULTS: 2 co-expression modules and 9 hub genes ((FCRL1/FCRL2/HELQ/EGR3LPL/LDOC1/ZNF667/SOWAHC/SEPTIN10) correlating with IGHV status were identified by WGCNA, and validated by external datasets. The modules were found to be enriched in NF-kappaB, HIF-1 and other important pathways, involving cell proliferation and apoptosis. The expression of hub genes was revealed to be significantly different, not only between CLL and normal B cell, but also between various types of lymphoid neoplasms. HELQ expression was found to be related with response of immunochemotherapy treatment significantly (p = 0.0413), while HELQ and ZNF667 were expressed differently between stable CLL and Richter syndrome patients (p < 0.0001 and p = 0.0278, respectively). By survival analysis of subgroups, EGR3 expression was indicated to be significantly associated with TTFT by 2 independent cohorts (GSE39671, p = 0.0311; GSE22762, p = 0.0135). While the expression of HELQ and EGR3 was found to be associated with OS (p = 0.0291 and 0.0114 respectively).The Kras, Hedgehog and IL6-JAK-STAT3 pathways were found to be associating with the expression of hub genes, resulting from GSEA. CONCLUSIONS: The expression of HELQ and EGR3 were correlated with IGHV mutation status in CLL patients. Additionally, the expression of HELQ/EGR3 were prognostic markers for CLL associating with targetable cell signaling pathways.
Authors: Cristina Gómez-Abad; Helena Pisonero; Carmen Blanco-Aparicio; Giovanna Roncador; Alberto González-Menchén; Jose A Martinez-Climent; Eva Mata; María Elena Rodríguez; Guillermo Muñoz-González; Margarita Sánchez-Beato; Juan F Leal; James R Bischoff; Miguel A Piris Journal: Blood Date: 2011-09-21 Impact factor: 22.113
Authors: S Cuní; P Pérez-Aciego; G Pérez-Chacón; J A Vargas; A Sánchez; F M Martín-Saavedra; S Ballester; J García-Marco; J Jordá; A Durántez Journal: Leukemia Date: 2004-08 Impact factor: 11.528
Authors: Sergey Krysov; Samantha Dias; Alex Paterson; C Ian Mockridge; Kathleen N Potter; Kelly-Ann Smith; Margaret Ashton-Key; Freda K Stevenson; Graham Packham Journal: Blood Date: 2011-11-15 Impact factor: 22.113
Authors: Adalgisa Condoluci; Lodovico Terzi di Bergamo; Petra Langerbeins; Manuela A Hoechstetter; Carmen D Herling; Lorenzo De Paoli; Julio Delgado; Kari G Rabe; Massimo Gentile; Michael Doubek; Francesca R Mauro; Giorgia Chiodin; Mattias Mattsson; Jasmin Bahlo; Giovanna Cutrona; Jana Kotaskova; Clara Deambrogi; Karin E Smedby; Valeria Spina; Alessio Bruscaggin; Wei Wu; Riccardo Moia; Elena Bianchi; Bernhard Gerber; Emanuele Zucca; Silke Gillessen; Michele Ghielmini; Franco Cavalli; Georg Stussi; Mark A Hess; Tycho S Baumann; Antonino Neri; Manlio Ferrarini; Richard Rosenquist; Francesco Forconi; Robin Foà; Sarka Pospisilova; Fortunato Morabito; Stephan Stilgenbauer; Hartmut Döhner; Sameer A Parikh; William G Wierda; Emili Montserrat; Gianluca Gaidano; Michael Hallek; Davide Rossi Journal: Blood Date: 2020-05-21 Impact factor: 22.113
Authors: Sascha Dietrich; Małgorzata Oleś; Junyan Lu; Leopold Sellner; Simon Anders; Britta Velten; Bian Wu; Jennifer Hüllein; Michelle da Silva Liberio; Tatjana Walther; Lena Wagner; Sophie Rabe; Sonja Ghidelli-Disse; Marcus Bantscheff; Andrzej K Oleś; Mikołaj Słabicki; Andreas Mock; Christopher C Oakes; Shihui Wang; Sina Oppermann; Marina Lukas; Vladislav Kim; Martin Sill; Axel Benner; Anna Jauch; Lesley Ann Sutton; Emma Young; Richard Rosenquist; Xiyang Liu; Alexander Jethwa; Kwang Seok Lee; Joe Lewis; Kerstin Putzker; Christoph Lutz; Davide Rossi; Andriy Mokhir; Thomas Oellerich; Katja Zirlik; Marco Herling; Florence Nguyen-Khac; Christoph Plass; Emma Andersson; Satu Mustjoki; Christof von Kalle; Anthony D Ho; Manfred Hensel; Jan Dürig; Ingo Ringshausen; Marc Zapatka; Wolfgang Huber; Thorsten Zenz Journal: J Clin Invest Date: 2017-12-11 Impact factor: 14.808